Compare TOMZ & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TOMZ | HIND |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 12.9M |
| IPO Year | 2009 | 2016 |
| Metric | TOMZ | HIND |
|---|---|---|
| Price | $0.56 | $2.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.50 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 50.9K | 26.4K |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,635,927.00 | N/A |
| Revenue This Year | $111.50 | N/A |
| Revenue Next Year | $57.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $1.75 |
| 52 Week High | $1.20 | $12.87 |
| Indicator | TOMZ | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 42.86 | 40.80 |
| Support Level | $0.54 | $2.02 |
| Resistance Level | $0.81 | $2.93 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 24.66 | 36.36 |
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage (7.8%) hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. Its product portfolio includes The SteraPak, The Surface Unit, The Transport, The NV+, The Environment System, SteraMist Integrated System, BIT Solution, and Custom Engineered System.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.